FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Sen. Johnson Wants Covid Interviews with Former FDAers, Fauci

[ Price : $8.95]

Sen. Ron Johnson asks to interview four former CBER officials and Anthony Fauci on the safety and efficacy of Covid vaccines.

Rybrevant Faspro sBLA Gets Priority Review for Head & Neck Cancer

[ Price : $8.95]

FDA accepts for priority review a Johnson & Johnson supplemental BLA for subcutaneous Rybrevant Faspro for adults with recurrent o...

Cerovene Cited for Repeat Manufacturing and Data Integrity Deficiencies

[ Price : $8.95]

FDA cites contract drug manufacturer Cerovene Inc. for repeat current good manufacturing practice deficiencies following a recent ...

Ways to Overcome Cancer Trial Site Activation Bottlenecks: Research

[ Price : $8.95]

A Friends of Cancer Research survey report documents bottlenecks in U.S. oncology clinical trial site scale-up activation and sugg...

Gasco Industrial Cited for Repeat Manufacturing Deficiencies

[ Price : $8.95]

FDA issues Gasco Industrial Corp. a Form 483 for significant and repeat GMP deficiencies following a 2/17-27 inspection of the com...

Argon Medical Convenience Kit Correction is Class I Recall

[ Price : $8.95]

FDA classifies a correction involving certain Argon Medical convenience kits as a Class I recall after identifying risks associate...

New FDA Flexibility in Cell and Gene Therapy Approvals

[ Price : $8.95]

A BioProcess International column praises a new FDA final guidance for introducing some flexibilities into approval of cell and ge...

FDA Proposed Rule Changes Facility Registration

[ Price : $8.95]

Two Argent Fox Schiff attorneys describe an FDA proposed rule that would change how some drug manufacturers register their facilit...

FDA Panel Backs Replimune Melanoma Therapy

[ Price : $8.95]

FDAs Cellular, Tissue, and Gene Therapies Advisory Committee votes to recommend approval of Replimune's experimental oncolytic imm...

New Effectiveness Evidence Requirements Analyzed

[ Price : $8.95]

Two Latham Watkins attorneys analyze a revised FDA draft guidance on demonstrating substantial evidence of effectiveness in drug a...